Neurotherapeutic Strategies for Multiple Sclerosis

Teresa C. Frohman, Shin C Beh, Eric J. Kildebeck, Ram Narayan, Katherine Treadaway, Benjamin Greenberg, Elliot Frohman

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.

Original languageEnglish (US)
Pages (from-to)483-523
Number of pages41
JournalNeurologic Clinics
Volume34
Issue number3
DOIs
StatePublished - Aug 1 2016

Fingerprint

Multiple Sclerosis
United States Food and Drug Administration
Therapeutics
Nervous System Diseases
Young Adult
Drug Therapy
Pregnancy

Keywords

  • Adrenocorticotrophic hormone
  • Corticosteroids
  • Disease-modifying therapy
  • Exacerbation
  • MS
  • Multiple sclerosis
  • Pregnancy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Neurotherapeutic Strategies for Multiple Sclerosis. / Frohman, Teresa C.; Beh, Shin C; Kildebeck, Eric J.; Narayan, Ram; Treadaway, Katherine; Greenberg, Benjamin; Frohman, Elliot.

In: Neurologic Clinics, Vol. 34, No. 3, 01.08.2016, p. 483-523.

Research output: Contribution to journalReview article

Frohman, Teresa C. ; Beh, Shin C ; Kildebeck, Eric J. ; Narayan, Ram ; Treadaway, Katherine ; Greenberg, Benjamin ; Frohman, Elliot. / Neurotherapeutic Strategies for Multiple Sclerosis. In: Neurologic Clinics. 2016 ; Vol. 34, No. 3. pp. 483-523.
@article{fe5a3def01c14615ad500fd9c5c3dd09,
title = "Neurotherapeutic Strategies for Multiple Sclerosis",
abstract = "Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.",
keywords = "Adrenocorticotrophic hormone, Corticosteroids, Disease-modifying therapy, Exacerbation, MS, Multiple sclerosis, Pregnancy",
author = "Frohman, {Teresa C.} and Beh, {Shin C} and Kildebeck, {Eric J.} and Ram Narayan and Katherine Treadaway and Benjamin Greenberg and Elliot Frohman",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.ncl.2016.05.001",
language = "English (US)",
volume = "34",
pages = "483--523",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Neurotherapeutic Strategies for Multiple Sclerosis

AU - Frohman, Teresa C.

AU - Beh, Shin C

AU - Kildebeck, Eric J.

AU - Narayan, Ram

AU - Treadaway, Katherine

AU - Greenberg, Benjamin

AU - Frohman, Elliot

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.

AB - Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.

KW - Adrenocorticotrophic hormone

KW - Corticosteroids

KW - Disease-modifying therapy

KW - Exacerbation

KW - MS

KW - Multiple sclerosis

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84992151461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992151461&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2016.05.001

DO - 10.1016/j.ncl.2016.05.001

M3 - Review article

C2 - 27445239

AN - SCOPUS:84992151461

VL - 34

SP - 483

EP - 523

JO - Neurologic Clinics

JF - Neurologic Clinics

SN - 0733-8619

IS - 3

ER -